Pharmacological interactions with darunavir

José Moltó; Marta Valle; Bonaventura Clotet

doi:10.1016/S0213-005X(08)76553-4

Pharmacological interactions with darunavir

José Moltó, Marta Valle, Bonaventura Clotet

Department of Medicine

Research output: Contribution to journal › Article › Research › peer-review

2 Citations (Scopus)

Abstract

Darunavir is a new HIV protease inhibitor that has been shown to be highly useful in HIV-infected patients. This drug is primarily metabolized by the liver through the cytochrome P450 3A4 (CYP3A4) isozyme and consequently coadministration with low doses of ritonavir markedly increases exposure and allows both daily doses and pill burden to be reduced. Both darunavir and ritonavir act as inhibitors and substrates of CYP3A4 and may therefore present pharmacological interactions with a large number of drugs commonly used in HIV-infected patients. The present review aims to summarize the main studies that have evaluated drug interactions and to provide recommendations on treatment with darunavir/ritonavir in clinical practice.

Original language	English
Pages (from-to)	43-50
Journal	Enfermedades Infecciosas y Microbiologia Clinica
Volume	26
Issue number	SUPPL. 10
DOIs	https://doi.org/10.1016/S0213-005X(08)76553-4
Publication status	Published - 1 Jan 2008

Keywords

Darunavir
Drug-drug interactions

Access to Document

10.1016/S0213-005X(08)76553-4

Fingerprint Dive into the research topics of 'Pharmacological interactions with darunavir'. Together they form a unique fingerprint.

Cite this

@article{996b5726bf8e4525a749ffd219acebf1,

title = "Pharmacological interactions with darunavir",

abstract = "Darunavir is a new HIV protease inhibitor that has been shown to be highly useful in HIV-infected patients. This drug is primarily metabolized by the liver through the cytochrome P450 3A4 (CYP3A4) isozyme and consequently coadministration with low doses of ritonavir markedly increases exposure and allows both daily doses and pill burden to be reduced. Both darunavir and ritonavir act as inhibitors and substrates of CYP3A4 and may therefore present pharmacological interactions with a large number of drugs commonly used in HIV-infected patients. The present review aims to summarize the main studies that have evaluated drug interactions and to provide recommendations on treatment with darunavir/ritonavir in clinical practice.",

keywords = "Darunavir, Drug-drug interactions",

author = "Jos{\'e} Molt{\'o} and Marta Valle and Bonaventura Clotet",

year = "2008",

month = jan,

day = "1",

doi = "10.1016/S0213-005X(08)76553-4",

language = "English",

volume = "26",

pages = "43--50",

journal = "Enfermedades Infecciosas y Microbiologia Clinica",

issn = "0213-005X",

publisher = "Ediciones Doyma, S.L.",

number = "SUPPL. 10",

}

TY - JOUR

T1 - Pharmacological interactions with darunavir

AU - Moltó, José

AU - Valle, Marta

AU - Clotet, Bonaventura

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Darunavir is a new HIV protease inhibitor that has been shown to be highly useful in HIV-infected patients. This drug is primarily metabolized by the liver through the cytochrome P450 3A4 (CYP3A4) isozyme and consequently coadministration with low doses of ritonavir markedly increases exposure and allows both daily doses and pill burden to be reduced. Both darunavir and ritonavir act as inhibitors and substrates of CYP3A4 and may therefore present pharmacological interactions with a large number of drugs commonly used in HIV-infected patients. The present review aims to summarize the main studies that have evaluated drug interactions and to provide recommendations on treatment with darunavir/ritonavir in clinical practice.

AB - Darunavir is a new HIV protease inhibitor that has been shown to be highly useful in HIV-infected patients. This drug is primarily metabolized by the liver through the cytochrome P450 3A4 (CYP3A4) isozyme and consequently coadministration with low doses of ritonavir markedly increases exposure and allows both daily doses and pill burden to be reduced. Both darunavir and ritonavir act as inhibitors and substrates of CYP3A4 and may therefore present pharmacological interactions with a large number of drugs commonly used in HIV-infected patients. The present review aims to summarize the main studies that have evaluated drug interactions and to provide recommendations on treatment with darunavir/ritonavir in clinical practice.

KW - Darunavir

KW - Drug-drug interactions

U2 - 10.1016/S0213-005X(08)76553-4

DO - 10.1016/S0213-005X(08)76553-4

M3 - Article

VL - 26

SP - 43

EP - 50

JO - Enfermedades Infecciosas y Microbiologia Clinica

JF - Enfermedades Infecciosas y Microbiologia Clinica

SN - 0213-005X

IS - SUPPL. 10

ER -